Effect of different doses of atorvastatin on chronic heart failure in patients with coronary heart disease
10.3969/j.issn.1005-1678.2017.08.056
- VernacularTitle:不同剂量阿托伐他汀治疗冠状动脉粥样硬化性心脏病慢性心力衰竭疗效分析
- Author:
Jinye CHEN
;
Jiaping YANG
;
Dong WANG
- Keywords:
Ato Vatatin;
heart failure;
coronary heart disease;
clinical efficacy
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(8):139-141
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the effect of different doses of atorvastatin in the treatment of coronary heart disease with chronic heart failure. Methods 100 patients with chronic heart failure who were admitted to Ankang Hospital from April 2013 to April 2016 were selected and randomly divided into the experimental group and the control group with a total of 50 patients in each group. Two groups of patients were treated with conventional treatment, the control group was given 20 mg of calcium a day, the experimental group was given a daily dose of 40 mg of calcium. The therapeutic effects of the two groups were compared. Results After treatment, the left ventricular end diastolic diameter in the control group was significantly higher than that in the experimental group, the left ventricular ejection fraction and E/A were significantly lower than those in the experimental group, and the difference was statistically significant (P<0.05). Patients in the control group were significantly higher than those in the experimental group in the incidence of cardiac death and recurrence of heart failure (P<0.05). Before treatment, there was no significant difference between the experimental group and the control group in serum NT-proBNP, hs-CRP levels and 6MWT. After treatment, the serum levels of NT-proBNP, hs-CRP in the control group were significantly higher than those in the experimental group, 6MWT was significantly shorter than that in the experimental group, and the difference was statistically significant (proBNP) (P<0.05). Conclusion Compared with 20mg/d, 40mg/d dose atorvastatin in the treatment of coronary heart disease with chronic heart failure curative effect, low recurrence rate, high safety, worthy of further promotion in clinical.
